Connect Biopharma is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T-cell-driven research.

With operations and expertise in China, the United States and Australia and clinical development activities in those geographies as well as Europe, Connect Biopharma is building a rich pipeline of internally designed, wholly owned small molecules and antibodies targeting several aspects of T cell biology. Our core expertise is in the use of functional cellular assays with T cells to screen and discover potent drug candidates against immune targets. Our two most advanced clinical-stage programs include potentially differentiated product candidates against validated targets.

We are supported by global top-tier investors:

Press Releases:

Posters and Publications:


There are no upcoming events scheduled at this time.

Investor Contact:

Ina McGuinness
Tel: +1 (805) 427-1372